The mechanisms by which complex lesions, particularly interstrand cross-links (ICLs), are removed or repaired in mammalian cells are poorly understood despite the importance to human health of compounds that induce these lesions. These agents, present in foodstuffs and produced as byproducts of mammalian metabolism, are highly toxic and mutagenic. Conversely, some of these drugs are also employed as highly active anti-tumor agents. The long term objectives of this application, involving four highly integrated projects and three cores, aim to elucidate the molecular mechanisms of repair of ICLs with the anticipation that the knowledge gained from these studies will be of significant value to understanding both the etiology of tumorigenesis and the enhancement of chemotherapeutic regimens. This proposed dissection of the mechanisms of ICL repair will encompass both mutagenic and non-mutagenic pathways, as well as the complete process of repair from lesion recognition to the final stages of restoration of helical integrity. Biochemical, molecular, and genetic approaches will be employed to elucidate of [sic] the mechanistic details of the multiple pathways of ICL repair. In addition, another objective of this application is to explore potential uses of ICL inducing compounds as a methodology to enhance recombination and mutagenesis in mammalian cells. Specifically, the use of triplex technology will be employed to direct ICLs to a particular genetic target. These approaches have excellent potential to yield useful technical and therapeutic advances in genetic manipulation.
This Project Summary describes a multicomponent Program Project with the theme of understanding the processing of complex DNA damage by mammalian cells. The significance to human health is to generate new knowledge and paradigms for modeling DNA repair of DNA interstrand crosslinks (ICLs), to improve therapy using ICL-inducing compounds, and to Identify new therapeutic targets for cancer treatment.
|Bacolla, Albino; Cooper, David N; Vasquez, Karen M (2014) Mechanisms of base substitution mutagenesis in cancer genomes. Genes (Basel) 5:108-46|
|Smith, Stephanie; Fox, Jennifer; Mejia, Marco et al. (2014) Histone deacetylase inhibitors selectively target homology dependent DNA repair defective cells and elevate non-homologous endjoining activity. PLoS One 9:e87203|
|Wood, Richard D; Lange, Sabine S (2014) Breakthrough for a DNA break-preventer. Proc Natl Acad Sci U S A 111:2864-5|
|Huang, Yaling; Leung, Justin W C; Lowery, Megan et al. (2014) Modularized functions of the Fanconi anemia core complex. Cell Rep 7:1849-57|
|Yousefzadeh, Matthew J; Wood, Richard D (2013) DNA polymerase POLQ and cellular defense against DNA damage. DNA Repair (Amst) 12:1-9|
|Wang, Yucai; Han, Xiao; Wu, Fangming et al. (2013) Structure analysis of FAAP24 reveals single-stranded DNA-binding activity and domain functions in DNA damage response. Cell Res 23:1215-28|
|Bacolla, Albino; Temiz, Nuri A; Yi, Ming et al. (2013) Guanine holes are prominent targets for mutation in cancer and inherited disease. PLoS Genet 9:e1003816|
|Huang, Yaling; Li, Lei (2013) DNA crosslinking damage and cancer - a tale of friend and foe. Transl Cancer Res 2:144-154|
|Wang, Yucai; Leung, Justin W; Jiang, Yingjun et al. (2013) FANCM and FAAP24 maintain genome stability via cooperative as well as unique functions. Mol Cell 49:997-1009|
|Leung, Justin Wai Chung; Wang, Yucai; Fong, Ka Wing et al. (2012) Fanconi anemia (FA) binding protein FAAP20 stabilizes FA complementation group A (FANCA) and participates in interstrand cross-link repair. Proc Natl Acad Sci U S A 109:4491-6|
Showing the most recent 10 out of 52 publications